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Abstract Subgroup analyses are commonly performed in the
clinical trial setting with the purpose of illustrating that the
treatment effect was consistent across different patient char-
acteristics or identifying characteristics that should be targeted
for treatment. There are statistical issues involved in
performing subgroup analyses, however. These have been
given considerable attention in the literature for analyses
where subgroups are defined by a pre-randomization feature.
Although subgroup analyses are often performed with sub-
groups defined by a post-randomization feature—including
analyses that estimate the treatment effect among compliers—
discussion of these analyses has been neglected in the clinical
literature. Such analyses pose a high risk of presenting biased
descriptions of treatment effects. We summarize the chal-
lenges of doing all types of subgroup analyses described in
the literature. In particular, we emphasize issues with post-
randomization subgroup analyses. Finally, we provide guide-
lines on how to proceed across the spectrum of subgroup
analyses.
Keywords Subgroup analyses . Post-randomization . Causal
inference .Multiplicity . Tests of interaction . Bias . A priori
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Introduction
Subgroup analyses are those that aim to estimate treatment
effects within subgroups of patients enrolled in a clinical trial.
They are performed frequently [1]. For example, Pocock and
others found in their review of comparative clinical trials that
51 % of the trials described in three high-impact journals
performed at least one subgroup analysis [2]. In a more recent
review, Parker and others found that 58 of 67 clinical trials
evaluating cardiovascular events performed subgroup analy-
ses [3]. Reasons that motivate such analyses include illustrat-
ing that the treatment effect is consistent across different
patient characteristics or identifying those patient characteris-
tics that should be targeted for treatment (e.g., gender, if
females respond well to the experimental therapy, whereas
males do not). Many publications of randomized clinical trials
include a forest plot, which displays the treatment effect across
a series of subgroups [4].
In their seminal paper on the topic, Yusuf and others
categorize subgroup analyses as those that are “proper” and
those that are “improper” [5]. The former involves subgroups
defined by a baseline characteristic that cannot be influenced
by treatment, whereas the latter defines subgroups on a post-
randomization feature, which may potentially be influenced
by the treatment itself. An analysis that examines effects by
gender, for example, falls into the category of proper subgroup
analyses. A common example of an improper subgroup anal-
ysis is a “per-protocol” analysis, defined as an analysis com-
paring outcomes by treatment group among those who ad-
hered to the assigned protocol—a feature measured after
initiation of the study. This is performed with the goal of
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drawing inference on the potential biological effect of
the experimental treatment. Because adherence (or any
post-randomization feature) may be influenced by the
actual treatment assigned, however, this can lead to
potentially biased estimates of treatment risk or benefit.
Much attention has been paid to proper or pre-
randomization subgroup analyses (e.g., [5–8]). In particular,
statisticians have raised concerns about the risk of
misinterpreting findings resulting from such analyses [2].
Clinical investigators have in turn expressed unease that by
maintaining statistical rigor, important scientific discoveries
could be missed (e.g., [9, 10]). We argue, however, that to
make good scientific discoveries, one must apply valid statis-
tical principles. To respond to the controversy, Yusuf and
others developed guidelines to consider when doing such
analyses [5]. Importantly, the guidelines only applied to prop-
er subgroup analyses. The authors advised against performing
post-randomization subgroup analyses, as the potential for
presenting biased treatment estimates is high. Similarly,
Assmann and others provided guidelines that applied to the
proper setting only, echoing the concerns raised byYusuf et al.
and advising against presenting findings from post-
randomization subgroup analyses [5, 6]. In fact, because these
analyses are deemed problematic, many investigators
reviewing the state of subgroup analyses neglected discussion
of post-randomization subgroup analyses in their reports (e.g.,
[2, 6, 7]). Hirji et al. noted, however, that not addressing issues
specific to post-randomization subgroup analyses has not
deterred their use or, perhaps more importantly, their influence
on clinical practice [1]. We generally agree that the issues
faced by both types of analyses should be addressed; investi-
gators continue to perform post-randomization subgroup anal-
yses and clinicians are faced with the task of interpreting the
findings, which may ultimately have influence on clinical
practice.
The goal of our paper is to summarize the challenges
and pitfalls in doing subgroup analyses described in the
literature. To that end, we summarize and expand upon
guidelines and solutions presented by previous investiga-
tors. Our paper emphasizes issues with post-randomization
subgroup analyses as these pose the additional complexity
of handling potential bias. Unfortunately, issues specific to
these analyses have also been neglected by the clinical
literature, as pointed out by Hirji and others [1]. There are
currently no guidelines for how to perform and report on
post-randomization subgroup analyses. Ours is the first to
provide guidelines on how to proceed across the spectrum
of subgroup analyses.
To that end, we searched for papers on PubMed
using the term “subgroup analysis” and chose those 21
papers spanning the years 1987 to 2013 and tabulated
challenges posed, guidelines presented, and solutions
provided [1–3, 5–21, 22•].
Challenges Encountered in Subgroup Analyses
Common pitfalls and challenges identified in previous studies
include increased type I error rates resulting from testing
multiple hypotheses, increased type II error rates caused by
testing hypotheses for which the study was not designed,
incorrect application of statistical tools for assessing hetero-
geneity across subgroups, testing data-driven (as opposed to
pre-specified) hypotheses, performing subgroup analyses
when overall findings are negative, considering hypotheses
not motivated by biology, and potential bias from performing
subgroup analyses where subgroups are defined by a post-
randomization feature. All of these challenges adversely im-
pact interpretation. Table 1 summarizes the corresponding
statistical implications of these challenges with high-level
solutions, which we describe in greater detail below.
Many of the issues raised are interrelated. Knowing wheth-
er an analysis was pre-specified (or specified a priori) versus
data-driven (or a posteriori) is important to consider for ap-
propriate interpretation. A posteriori tests are circular in that
one can examine differences in effect by many possible sub-
groups, find something interesting, and then formulate a hy-
pothesis to test the interesting finding. In this way, the testing
leads to a hypothesis of interest to be tested. If the purpose of
the examination of the data is to generate hypotheses, the
newly generated hypothesis should be tested on an indepen-
dent data set and not the data set upon which the hypothesis
was generated. A priori tests, in contrast, are pre-specified—
typically based on biological understandings and/or previous
findings in the literature. The hypothesis has been formulated
prior to examination of the data, and therefore, the results
support or refute the hypothesis rather than the other way
around. Thus, knowledge of which type of analysis was
performed provides context in which to interpret the findings
[5, 11, 12, 17].
Along similar lines, several authors discuss the importance
of biological plausibility as one of the criterion for performing
subgroup analyses [11, 17]. Altman [16], however, believes
this is the weakest of the four criteria put forward by Furberg
and Byington [23] to providing credibility for a finding, as he
believes clinical investigators can always find a biologically
plausible explanation for any finding.
The issues described above (a priori specification and
biological plausibility) are both related to another issue—that
of multiplicity or multiple testing. Several authors raised this
issue, which affects interpretation in that it can lead to false-
positive findings and/or an overemphasis of findings [1, 5, 7,
16, 20]. Key to appropriate interpretation is knowledge of how
many subgroup analyses have been performed. Note that even
when there is no difference in treatment effect by subgroups,
when testing 20 uncorrelated hypotheses at the 0.05 level of
significance, we would expect 1 of these tests to be incorrectly
rejected (or falsely positive). Compare an evaluation of 2
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hypotheses where one was found positive, to an evaluation of
20 hypotheses where 1 was found positive. We can have more
confidence in the positive test that was based on 2 hypotheses
than the positive test from 20. Statistically, we can more
formally address this by using methods to appropriately con-
trol the family-wise error rate (e.g., through use of a
Bonferroni correction) or the false-discovery rate depending
on the research question [24, 25].
Prevalent in the literature is a tendency to incorrectly assess
heterogeneity of treatment effects [1, 2, 5–7, 16, 21]. This is
done by testing for treatment effects within each level of the
subgroup of interest (e.g., evaluating the treatment effect
among males and among females if gender is of interest)
and then comparing p values or point estimates across sub-
groups informally to determine whether effects are heteroge-
neous. This is problematic, as some random heterogeneity is
expected across factors. Whether the observed heterogeneity
is larger than expected by chance needs to be addressed
through formal use of statistical tests of interaction like the
Breslow-Day test, the Mantel-Haenszel test, or the interaction
test from a modeling procedure [26].
Clinical trials are rarely designed to evaluate differences in
treatment effect in subgroups, yielding low power to investi-
gate such differences and increasing the type II error rate of the
hypothesis. In other words, if the study is not designed to
discern differences in heterogeneity across subgroups, there is
a high probability of incorrectly concluding there are no
differences even when there are [5]. For example, suppose a
2-arm study investigating a new experimental therapy for
breast cancer requires 240 patients or 120 subjects per arm
to have 80 % power to detect a hazard ratio of 1.5 assuming
50 % of the subjects in the standard treatment arm are event
free at 6 months. If we wanted to examine whether these
differences varied by low- versus high-grade tumors and if
we assumed that half of enrolled patients would be diagnosed
with low-grade tumors, wewould need 449 patients per arm to
have 80 % power to detect differential treatment effects by
grade assuming no difference in hazard rates between treat-
ment arms among those diagnosed with low-grade tumors and
a hazard ratio of 2 for those diagnosed with high-grade tu-
mors. With a sample size of 240, there is less then half the
chance (48 %) to detect differential treatment effects by grade.
Further, if the proportion of subjects with high- versus low-
grade tumors is imbalanced, as is typically the case, this will
require an even larger increase in the sample size. Suppose
70 % of those enrolled have high-grade tumors and only 30 %
have low-grade tumors, then 517 subjects would be required
to have 80 % power to detect this difference in hazard ratios,
where the current design only gives a 40 % chance of detect-
ing the difference. Thus, unless there is strong a priori evi-
dence to motivate redesigning the trial, the study will not be
designed to assess differences across most subgroups. Not
having sufficient evidence to support heterogeneity of effects
with such a high type II error rate could mislead investigators
into concluding effects are homogenous.
Concerns have been raised in performing subgroup analy-
ses when the overall trial results did not achieve statistical
significance for the primary hypothesis [2, 7, 11]. Often, these
analyses are performed to salvage a “negative” trial or to learn
from the trial about future areas of investigation. This may
create confusion for the reader and is generally not recom-
mended. Bulpitt specified four criteria that should hold before
subgroup analyses are pursued, which included that the over-
all findings be positive before proceeding, where the other
three were that the hypotheses were biologically plausible,
pre-specified, and that the analysis was not inherently subject
to bias [11]. If the overall findings are negative, the question of
which subgroups benefit more or less is no longer relevant and
any so-called positive findings based on subgroup analyses
are then challenging to interpret.
Table 1 Recognized pitfalls and
solutions for subgroup analysis as
described in the literature
Statistical issue Potential solutions
Increased type I error rate (false-positive findings) Limit the number of analyses performed to those
that are pre-specified and biologically plausible
Adjust for multiplicity
Increased type II error rate (low power
to detect interesting findings)
Design study to examine particularly relevant subgroups
Biased estimates of treatment Limit to performing proper analyses
Findings are difficult to interpret Emphasize overall findings
Utilize formal tests of interaction to appropriately
assess heterogeneity of effects
Do not perform subgroup analyses if overall findings
are negative
Report the number of tests performed
Report the number of tests that were specified a
priori and the number that were specified a posteriori
Report all findings—positive and negative
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Another issue that impedes interpretation is selective
reporting. Whereas not all findings warrant detailed reporting,
all analyses performed do. In order for the reader to have an
appropriate context to interpret the findings presented by the
author as interesting or relevant, the analyses that were per-
formed, the number, whether they were pre-specified, and
which were negative and positive should be provided [2].
Specific to post-randomization subgroup analyses is the
issue of bias, requiring special attention to be paid to the
methods employed and interpreted. Pre-randomization sub-
group analyses compare subjects by baseline features which
are unaffected by treatment assignment. Consequently, in
theory, these subgroups should be comparable because ran-
domization principles should still apply. It is standard for most
clinical trials to specify an intent-to-treat (ITT) analysis as the
primary analysis. Such an analysis can be described as an
inclusive analysis. All subjects randomized to treatment are
included in the analysis and analyzed by their randomized
treatment assignment regardless of adherence. Because it
maintains randomization, it has good statistical properties for
testing the null hypothesis of no treatment effect [27]. Many
investigators are uncomfortable accepting these ITT findings
without further analyses, however, because of issues related to
adherence or loss-to-follow-up. A post-randomization sub-
group analysis called a “per-protocol” analysis is consequent-
ly proposed, where only those subjects who fulfill the protocol
in terms of eligibility, interventions, and assessments are in-
cluded in the analysis. Those who complete the trial and
adhere to the assigned protocol, however, are typically differ-
ent from those who do not, and this can induce a bias when
estimating the treatment effect. For example, suppose a study
is evaluating the effect of a new experimental therapy (arm A)
on reducing cardiovascular events relative to standard therapy,
and suppose that arm A is actually harmful. As a result, those
assigned to arm A are more likely to observe changes in their
lipid profile and, consequently, stop adhering to the study
drug, making them more likely to be excluded from the
analysis. This may make arm A look more favorable or less
harmful than it actually is.
Pieper and others illustrated the danger of post-
randomization subgroup analyses with another important ex-
ample in cardiovascular medicine [20]. While many believe
that treatment of platelet glycoprotein (GP) IIb/IIIa inhibition
should be used only in acute coronary syndrome (ACS) pa-
tients undergoing percutaneous coronary intervention (PCI),
Pieper and others argue that the evidence to support this is
based on problematic subgroup analyses that fall into the
improper category and that therefore yield potentially mis-
leading descriptions of treatment effects. In clinical trials
evaluating the benefit of GP in non-ST-elevation ACS pa-
tients, questions of which subtypes of patients would most
benefit have been addressed through series of subgroup anal-
yses. One targeted subgroup has been those patients
undergoing PCI versus those receiving medical management
only. Specifically, whether the benefits differ between these
two groups of ACS patients has been a subject of debate.
Because undergoing PCI is not a characteristic known at
baseline, but rather defined by an event that occurs at some
point post-randomization, subjects in subgroups defined by
the performance of a PCI or not post-randomization may
differ by factors other than PCI. For example, this subgroup
assignment may relate to their underlying disease and/or im-
portantly may have been influenced by the treatment itself.
Suppose GP inhibitors make PCI less necessary so that those
in the control group undergo PCI at a higher rate, and further
that those undergoing PCI in the treatment group are inher-
ently different from those undergoing PCI in the control
group. In general, if the reason for PCI differs for subjects
exposed to GP inhibitors versus those in the control group,
this can make PCI patients exposed to treatment fundamen-
tally different from those not exposed to treatment, potentially
confounding the treatment effect.
Below, we discuss some possible solutions to minimize or
address bias inherent in post-randomization subgroup
analyses.
Potential Solutions for Addressing or Minimizing Bias
Encountered in Post-Randomization Subgroup Analyses
There are statistical tools that can be used to minimize poten-
tial bias induced by post-randomization subgroup analyses.
For evaluating whether GP inhibitors reduce ischemic events
in patients with ACS by PCI versus medical management,
Pieper and others offer four alternative solutions to the stan-
dard analytic approach of post-randomization subgroups [20].
In a standard subgroup analysis, the assignment of a patient to
the PCI subgroup is treated as static (i.e., if a patient undergoes
PCI at any point during the observation period, the patient is
placed in the PCI subgroup. Otherwise, the patient is consid-
ered to have undergone medical management only). This
categorization can be problematic particularly if an event such
as a myocardial infarction (MI) occurred prior to receiving
PCI (i.e., during the period when the patient had only received
medical management), and furthermore, the MI may have
influenced the patient to have the PCI. To address this issue,
the authors suggest the following four approaches:
& Classify subjects as in the standard approach but exclude
any events that occurred prior to the PCI. By doing this,
the authors minimize bias due to potential confounding by
indication.
& Analyze subjects during the medical management period
only, so that subjects are observed until the first occur-
rence of the relevant ischemic event, PCI, or the end of
study, whichever occurs first, using survival analytic
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techniques. In this solution, the treatment effect is evalu-
ated under medical management. One cannot, however,
evaluate the differential treatment effect for those who
undergo PCI versus medical management. Like the first
solution, however, this approach offers a method to eval-
uate the treatment effect by minimizing potential con-
founding of PCI.
& Consider PCI as a time-varying variable and make use of
survival analytic techniques that incorporate time-depen-
dent confounders. In such an analysis, the subject contrib-
utes data to the medical management group during the
time period prior to the subject’s PCI. If the subject had a
PCI, the subject contributes data to the PCI group after this
point. The authors point out that this approach does not
address inherent selection bias, however.
& Directly address the selection bias through use of propen-
sity score methods [28]. Under certain assumptions, such
an approach would also allow evaluation of heterogeneity
of effects between PCI and medical management groups
through use of an interaction term.
The challenge of bias faced by post-randomization sub-
group analyses are similar to those that many observational
studies face, particularly those in the longitudinal setting, and
as Pieper and others suggest, we can borrow tools used in
those settings for drawing causal inference while being mind-
ful of their limitations [20]. The idea behind the proposed
propensity score method is that one can use observed infor-
mation to model the propensity for the exposure or treatment
of interest and use this to adjust for confounding between
groups of interest. There are numerous ways in which pro-
pensity scores can be incorporated into the analysis (e.g.,
through matching in the design, stratification, through inclu-
sion as a covariate in the model, or inverse probability
weighting) [29•]. An interaction term between PCI and treat-
ment can then evaluate whether the treatment effect differs for
those who do and do not undergo PCI. Validity of the results
relies on an assumption that the propensity for undergoing
PCI can be modeled by observed variables only. Under this
assumption, the estimated treatment effect is unbiased.
However, this particular approach only includes baseline char-
acteristics to predict PCI use. Newer methods have been
developed and will be discussed, which allow the propensity
to change over time.
Other causal inference tools that can be applied include the
use of instrumental variables or, more generally, principal
stratification methods, and marginal structural models [14,
15, 30, 31]. The idea behind instrumental variables is to
identify an instrument or variable that has a causal relationship
with treatment assignment but no direct causal relationship to
the outcome to use in evaluating the effect of interest. This
approach is discussed in detail in the context of assessing
treatment effects among compliers and relies upon strong
assumptions involving the instrument [14]. Marginal structur-
al models can be used in this context as well. The idea behind
marginal structural models is to weigh subjects by the proba-
bility of being in the post-randomization subgroup and the
randomly assigned study therapy. Subjects are weighted to
appropriately represent the population by creating a
pseudopopulation. These probabilities can be based on factors
that change over time. Suppose among those undergoing PCI,
those assigned to the treatment arm had higher comorbidities
than those assigned to the control arm. Ideally, we would have
for a person in the treatment arm with a high comorbidity, a
similar person on the control armwith a high comorbidity—as
you would imagine in a randomized setting, but due to con-
founding factors, that counterpart is “missing.” Weights are
then estimated based on patient characteristics, which can be
incorporated into the analysis in order to create a more repre-
sentative sample. Their validity relies on an assumption that
weights can be well estimated by observed characteristics. A
limitation therefore is that only measured clinical features can
be included in the weighting, and non-measured factors may
be important.
Hirji et al. offer two alternative solutions to what they term
outcome-based subgroup analyses—a special case of post-
randomization subgroup analyses, where subgroups are de-
fined based on an outcome and the interest is in examining a
different outcome [1]. An example they provide is evaluating
quality of life among survivors of a cancer trial. The solutions
involve single imputation of possible outcomes for those
missing data. In the example of the quality of life study, this
would involve imputing the worst value for those who did not
survive, instead of excluding them from the analysis. Single
imputation methods, however, are shown to be biased as they
do not appropriately account for the uncertainty of the impu-
tation process [32, 33]. In this case, where the data are likely to
be not missing at random, we agree with Hirji and others that
standard multiple imputation, which relies on a missing at
random assumption, is not recommended [1]. However, mul-
tiple imputation-based methods can still be applied under a
not-missing-at-random assumption, although its implementa-
tion increases in complexity [33]. Although more complicat-
ed, we recommend this approach over that proposed by Hirji
et al. [1]. In particular, we recommend considering plausible
distributions from which to impute, as Hirji et al. did in the
single imputation context, but we further recommend averag-
ing over the uncertainty of these choices [1, 33].
Finally, we recommend performing sensitivity analyses, as
Pieper and others did, to demonstrate variability in findings as
modeling assumptions vary [20]. Consistency across analyses
strengthens the evidence, and disparate results should trigger
further examination to enable insight into what may be
influencing particular findings. They also provide a fuller
context for the reader to interpret. Below, we summarize these
guidelines.
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Our Guidelines for Pre- and Post-Randomization
Subgroup Analyses
Yusuf and others provided excellent and detailed guidelines
for analyzing pre-randomization subgroups [5]. This was
followed more recently by Wang and others who provided
comprehensive guidelines for reporting findings from these
subgroup analyses [7]. We build upon these recommendations
and expand them to include guidelines for post-randomization
subgroup analyses as well (Table 2).
Pre-Specify and Define the Subgroups in the Design Phase
Like Yusuf et al., we too recommend starting in the design
phase [5]. Here, one should state a priori all biologically
plausible subgroup analyses that should be considered and
rank the corresponding hypotheses in order of importance.
See the recent publication by Thomas and Peterson describing
their recommendations on pre-specifying analyses in the
observational setting where similar discussions are taking
place [34].
Limit the Number of Subgroups
We recommend limiting this number, keeping in mind that
methods to adjust for multiplicity should be applied to ensure
meaningful interpretation. Consequently, too many pre-
specified hypotheses may make it impossible to observe any
interesting differences when adjusting for multiplicity. To aid
in this, calculating the power with a conservative Bonferroni
correction and meaningful effect size will provide insight into
feasibility. If the power is inadequate, the investigator should
consider the importance of including the analysis (the ranking
will be helpful here). At this point, the investigator can decide
whether to adjust the study design accordingly by increasing
the sample size to allow for its evaluation. We recommend
writing out the specific analysis plan for the subgroup analy-
ses. This will also help with the subsequent guideline of
determining precisely what can be concluded from the pro-
posed analysis. Oftentimes, it is not clear exactly what con-
clusions one can derive from a proposed analysis. Stating this
beforehand can clarify whether the choice of subgroup anal-
ysis as defined is appropriate and can prevent the generation of
a posteriori subgroup analyses, which should be treated dif-
ferently in the interpretation and given much less weight in
importance.
Formally Test for Heterogeneity Using Statistical Tests
of Interaction and Methods to Correct for Multiplicity
Widespread in the literature are inappropriate comparisons
across levels of subgroups where investigators incorrectly
conclude there are or are no differences in treatment effect
by informally comparing p values or point estimates. Formal
tests of interaction will appropriately address whether effects
are heterogeneous beyond variation expected by chance. Use
of such methods is encouraged and easy to use with any
statistical software. Also, we agree with Yusuf and others that
while p values and tests of significance can be applied to those
subgroup analyses that were pre-specified, they are not mean-
ingful for those that are data-driven, and should therefore not
be reported [5]. Instead, data-driven hypotheses should be
tested in an external or independent data set. We additionally
recommend applying methods to control either the family-
wise error rate or the false-discovery rate.
Explore Causal Inference Methods for Post-Randomization
Subgroups
We recommend exploring the use of causal inference methods
like instrumental variables, marginal structural models, or
propensity scores. We acknowledge, however, that these tools
Table 2 Guidelines for performing subgroup analyses that build upon
those provided by Yusuf et al. (1991)
Design
State plausible subgroup hypotheses and note which are defined by
post-randomization features
Rank hypotheses in order of plausibility
Calculate power. Consider adjusting the design if necessary
State methods for analysis and be specific (i.e., include functional form
of all relevant variables—continuous or categorical and if
categorical, specify the cut-offs)
State conclusions that can be drawn from the analysis plan and any
resulting decisions that may occur as a consequence of the findings
Analysis
Use tests of interaction to formally assess heterogeneity of effects
Distinguish between a priori and data-driven hypotheses. Do not
present p values for data-driven hypotheses
Adjust for multiplicity for a priori subgroup analyses
If post-randomization:
• Consider causal inference tools
• Consider method for incorporating time into model
•Consider sensitivity analyses, where several models are fit and results
compared across models
Interpretation and reporting
Report findings corresponding to primary hypothesis
Report the number of a priori hypotheses tested
Report the number of data-driven hypotheses examined
Interpret findings in the context of previous studies and/or similar data
from other trials, and based on biological plausibility
Consider pooling findings for subgroup analyses with other studies
Consider external data set where methods can be applied to replicate
findings and/or provide code for fitting model, particularly if a post-
randomization analysis was conducted so that other investigators can
more easily replicate
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are limited. In particular, if unobserved confounders exist, or
an instrument that fulfills necessary criteria is not identified,
the problem may be intractable. In addition, it may be feasible
to consider approaches to incorporate time into the analysis, as
Pieper and others did, for example, by not considering events
that occurred prior to the occurrence of PCI [20].
Perform Sensitivity Analysis for Post-Randomization
Subgroups
Due to the high risk of providing biased results, sensitivity
analyses that vary models/assumptions should be performed
to show how these assumptions may influence the findings.
The variation in findings will help the reader to weigh the
evidence.
Report on All Analyses Performed, Whether Positive
or Negative
For the interpretation and reporting phase, we borrow ideas
from both Yusuf et al. and Wang et al. [5, 7]. Wang and others
recommend reporting the number of pre-specified subgroup
analyses performed as well as the number of data-driven
analyses [7].
Focus on the Findings that Correspond to the Primary
Hypothesis
We agree with Yusuf et al., Wang et al., and Pieper et al. that
the emphasis of the report should center around the main
findings—those that correspond to the primary hypothesis
[5, 7, 20]. All other analyses for which the study was not
designed should receive considerably less attention.
Provide a Context in Which the Reader Can Interpret
the Study’s Findings
Yusuf et al. recommend putting in context the study’s findings
with those of previous studies of similar design/data and
making sense of any discrepancies [5]. This involves
reflecting on the study’s design and/or methodological limita-
tions, and/or the appropriateness/generalizability of the study
population. Taking this one step further may be to pool the
findings with other studies in a meta-analysis or pooling the
data with that from other studies in a pooled analysis (if
appropriate) to summarize findings across studies [35]. One
can also set up next steps for other authors to replicate the
findings in either another population to assess generalizability
or in another data set of a similar population to validate the
findings. Providing code to do this is key as details provided in
most papers given their word limitations may not be sufficient
for others to apply the exact methods employed. Precise
implementation of the methods used is crucial for replication.
Conclusions
Post-randomization subgroup analyses face the same chal-
lenges as those encountered in pre-randomization subgroup
analyses. There is one crucial difference. Because post-
randomization subgroups are defined by a feature measured
at some point during the study, estimates of treatment are
potentially biased. Analyses that thoughtfully incorporate time
into the model and/or that attempt to minimize the bias should
be considered. Issues raised for pre-randomization subgroup
analyses should also be considered. And importantly, for all
subgroup analyses, the findings from the primary hypothesis
should be emphasized whether negative or positive. All other
findings should be considered hypothesis-generating.
Replication and/or pooling are important tools that can
be used to strengthen evidence for positive findings that
result from such analyses. Evidence must reach a certain
level, however, before it can be considered in influenc-
ing clinical practice, and subgroup analyses—post or
pre-randomization—do not reach this level. They do have
their place, however, and can appropriately affect the direction
of new science, if performed thoughtfully. Our study helps to
synthesize the key issues to consider in such analyses and
provides general guidelines for approaching subgroup
analyses.
Compliance with Ethics Guidelines
Conflict of Interest Manisha Desai and Karen S. Pieper declare that
they have no conflict of interest.
Ken Mahaffey reports grants and personal fees from Johnson &
Johnson, grants from Regeneron, grants and personal fees from Cubist
Pharmaceuticals, grants and personal fees from Sanofi, grants from
Baxter, grants from Roche Diagnostics, grants from Ikaria, grants from
Amgen, grants from Regado, grants and personal fees fromMerck, grants
and personal fees from Glaxo Smith Kline, grants from Amylin, grants
from Novartis, grants and personal fees from AstraZeneca, grants from
Portola, grants and personal fees from Eli Lilly, grants from Edwards
Lifesciences, grants and personal fees from Boehringer Ingelheim, grants
from the National Institute of Health, grants from the National Heart,
Lung & Blood Institute, grants from the National Institute of Allergy &
Infectious Diseases, personal fees from Bayer, personal fees from
Biotronik, personal fees from Daiichi Sankyo, personal fees from
Gilead Sciences, personal fees from Medtronic, personal fees from
Ortho/McNeill, personal fees from Pfizer, personal fees from St. Jude,
personal fees from ACC, personal fees from John Hopkins University,
personal fees from South East Area Health Education Center, personal
fees from Sun Pharma, grants and personal fees from Bristol Myers-
Squibb, personal fees from the Duke Center for Educational Excellence,
personal fees from the University of British Columbia, personal fees from
WebMD, personal fees from Perdue Pharma, personal fees from
Dialogues, personal fees from Springer Publishing, personal fees from
Haemonetics, personal fees from Forest, personal fees from Amgen, and
personal fees from Elsevier. He also reports other relationships: www.
dcri.org and www.med.stanford.edu/profiles/.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Curr Cardiol Rep (2014) 16:531 Page 7 of 8, 531
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
1. Hirji KF, Fagerland MW. Outcome based subgroup analysis: a
neglected concern. Trials. 2009;10:33.
2. Pocock SJ, HughsMD, Lee RJ. Statistical problems in the reporting
of clinical trials. N Engl J Med. 1987;317(7):426–32.
3. Parker AB, Naylor CD. Subgroups, treatment effects, and baseline
risks: some lessons from major cardiovascular trials. Am Heart J.
2000;139(6):953–961.4.
4. Pocock SJ, Travison TG,Wruck LM. Figures in clinical trial reports:
current practice & scope for improvement. Trials. 2007;8:36.
5. Yusuf S, Wittes J, Probstfield J, Tyroler H. Analysis and interpre-
tation of treatment effects in subgroups of patients in randomized
clinical trials. JAMA. 1991;266(1):93.
6. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis
and other misuses of baseline data in clinical trials. Lancet.
2000;355:1064–9.
7. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics
in medicine—reporting of subgroup analyses in clinical trials. N
Engl J Med. 2007;357(21):2189–94.
8. Alosh M, Huque MF. Multiplicity considerations for subgroup
analysis subject to consistency constraint. Biom J. 2013;55(3):
444–62.
9. Stallones RA. The use and abuse of subgroup analysis in epidemi-
ological research. Prev Med. 1987;16:183–94.
10. Feinstein AR. The problem of cogent subgroups: a clinicostatistical
tragedy. J Clin Epidemiol. 1998;51(4):297–9.
11. Bulpitt, CJ. Medical statistics. The Lancet 1988; 31–34.
12. Buyse ME. Analysis of clinical trial outcomes: some comments of
subgroup analyses. Control Clin Trials. 1989;10:187S–94.
13. Schneider B. Analysis of clinical trial outcomes: alternative ap-
proaches to subgroup analysis. Control Clin Trials. 1989;10:
176S–86.
14. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects
using instrumental variables. J Am Stat Assoc. 1996;91(434):444–55.
15. Imbens, Rubin. Estimating outcome distributions for compliers in
instrumental variable models. Rev Econ Stud. 1994;64:555–74.
16. Altman D. Within trial variation—a false trail? J Clin Epidemiol.
1998;51(4):301–3.
17. Adams Jr KF. Post hoc subgroup analysis and the truth of a clinical
trial. Am Heart J. 1998;136:753–8.
18. Julian DG. Debate: a subversive view of subsets—a dissident
clinician’s opinion. Curr Control Trials Cardiovasc Med. 2000;1:
28–30.
19. Sleight P. Debate: subgroup analyses in clinical trials—fun to look
at, but don’t believe them! Curr Control Trials Cardiovasc Med.
2000;1:25–7.
20. Pieper KS, Anastasios AT, DavidianM, Hasselblad V, Kleiman NS,
Boersma E, et al. Differential treatment benefit of platelet glyco-
protein IIb/IIa inhibition with percutaneous coronary intervention
versus medical therapy for acute coronary syndromes: exploration
of methods. Circulation. 2004;109:641–6.
21. Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin
Pract Rheumatol. 2007;3(7):407–13.
22.• Altstein L, Li G. Latent subgroup analysis of a randomized clinical
trial through a semiparametric accelerated failure time mixture
model. Biometrics. 2013;69:52–61. This paper illustrates a novel
statistical approach for drawing causal inference when performing
post-randomization subgroup analyses with the goal of estimating
the biological effect of an experimental therapy.
23. Furberg CD, Byington RP.What do subgroup analyses reveal about
differential response to beta-blocker therapy? The Beta-Blocker
Heart Attack Trial experience. Circulation. 1983;67(6):98–101.
24. Hochberg Y, Tamhane A. Multiple comparison procedures. New
York: Wiley; 1987.
25. Benjamini, Hochberg. Controlling the false discovery rate: a prac-
tical and powerful approach to multiple testing. J R Stat Soc Ser B.
1995;57(1):289–300.
26. Agresti A. An introduction to categorical data analysis, 2nd edition.
Wiley-Interscience; 2007.
27. Piantadosi S. Clinical trials: a methodological perspective, 2nd
edition. Wiley Series in Probability and Statistics; 2005.
28. Rosenbaum P, Rubin DB. The central role of the propensity score in
observational studies for causal effects. Biometrika. 1983;70(1):41–
55.
29.• Austin PC. An introduction to propensity score methods for reduc-
ing the effects of confounding in observational studies. Multivar
Behav Res. 2011;46:399–424. This paper gives a nice introduction
to propensity scores and describes four approaches that can be
applied to estimate causal effects for post-randomization subgroup
analyses.
30. Frangakis CE, Rubin DB. Principal stratification in causal infer-
ence. Biometrics. 2002;58(1):21–9.
31. Robins J, Hernan M, Brumback B. Marginal structural models and
causal inference in epidemiology. Epidemiology. 2000;11(5):550–
60.
32. Allison P. Missing data. Series: quantitative applications in the
social sciences. A SAGE University Paper; 2001.
33. Little, Rubin. Statistical analysis with missing data. New York: J.
Wiley & Sons; 1987.
34. Thomas L, Peterson ED. The value of statistical analysis plans in
observational research: defining high-quality research from the
start. J Am Med Assoc. 2012;308(8):773–4.
35. Borenstein M, Hedges L, Higgins J, Rothstein HR. Introduction to
meta-analysis. Wiley; 2009.
531, Page 8 of 8 Curr Cardiol Rep (2014) 16:531
